Ezetimibe added to statin therapy after acute coronary syndromes
暂无分享,去创建一个
[1] John Spertus,et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. , 2014, The New England journal of medicine.
[2] U. Laufs,et al. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. , 2014, European heart journal.
[3] R. Califf,et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. , 2014, American heart journal.
[4] Sarah Parish,et al. Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.
[5] Markus Abt,et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[6] W. Weintraub,et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. , 2012, Atherosclerosis.
[7] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[8] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[9] Paul Welsh,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.
[10] M. Gnant,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .
[11] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[12] R. Califf,et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. , 2010, American heart journal.
[13] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[14] R. Califf,et al. Premature release of data from clinical trials of ezetimibe. , 2009, The New England journal of medicine.
[15] R. Califf,et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.
[16] R. Califf,et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.
[17] Allen J. Taylor,et al. Preliminary Observations From Preliminary Trial Results: Have We Finally Had Enough? , 2008, Circulation. Cardiovascular quality and outcomes.
[18] Christopher P Cannon,et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.
[19] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[20] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[21] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[22] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[23] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[24] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[25] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[26] C. Ballantyne,et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. , 2004, The American journal of cardiology.
[27] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[28] I. Holme,et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.
[29] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[30] Barry R. Davis,et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.
[31] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[32] D. Tribble,et al. Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans , 2002, Circulation.
[33] D. Cutler,et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin , 2002 .
[34] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[35] P. Serruys,et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[36] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[37] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[38] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[39] Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.
[40] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[41] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[42] Y. Hochberg. A sharper Bonferroni procedure for multiple tests of significance , 1988 .